Magnetic Nanoparticles with Polymer Shells for MRI Contrast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional MRI contrast agents face challenges with stability, pharmacokinetics, and penetration through biological barriers like the blood-brain barrier, limiting their effectiveness for neuronal disease diagnosis and exposing patients to radiation with PET and CT scans.
Innovation Solution
Development of magnetic nanoparticles with a metal core and a polymer shell coating, comprising a polyethylene glycol: polylactic acid coblock polymer and polyvinylpyrrolidone, which improves stability, circulation half-life, and reduces toxicity, allowing for enhanced penetration of the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MRI contrast agents are used, then imaging capability is provided, but stability and pharmacokinetics are poor leading to agglomeration and short half-life
Solution Approach 1:
The patent uses composite materials by coating metal cores with multiple polymer layers (inner shell and outer shell) to create a stable nanoparticle structure. The inner shell provides structural integrity while the outer shell provides biocompatibility and stability in physiological environments, preventing agglomeration and improving pharmacokinetics.
Solution Approach 2:
The patent employs flexible polymer shells coating the metal core to prevent agglomeration. The polymer coating forms a protective thin film that maintains nanoparticle dispersion in biological fluids, improving stability and circulation half-life without compromising the magnetic imaging function.
2Measurement precision
If targeting agents are conjugated to improve specificity, then target binding is enhanced, but toxicity increases and molecular weight increases inhibiting penetration through biological barriers
Solution Approach 1:
The patent applies local quality by functionalizing only the outer surface of the nanoparticle with targeting moieties, while the core and inner shell remain biocompatible and non-toxic. This localized functionalization provides target specificity without requiring high molecular weight conjugates that would increase toxicity or hinder blood-brain barrier penetration.
3Measurement precision
If PET or CT scans are used for neuronal disease diagnosis, then diagnostic capability is provided, but patients are exposed to radiation increasing risk for continuous monitoring
Solution Approach 1:
The patent replaces radiation-based diagnostic methods (PET/CT) with magnetic resonance imaging based on magnetic fields and radio waves. This substitution eliminates ionizing radiation exposure while maintaining diagnostic capability for neuronal diseases, enabling safer continuous monitoring.
4Reliability
If MRI contrast agents are coated with biocompatible polymers to prevent agglomeration, then stability is improved, but complexity of the formulation increases
Solution Approach 1:
The patent segments the polymer coating into distinct functional layers: an inner shell for structural stability and an outer shell for biocompatibility and circulation stability. This segmentation allows each layer to be optimized for its specific function while maintaining overall formulation simplicity through a systematic multi-layer architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles provide improved long-term stability, enhanced pharmacokinetics, and reduced toxicity, enabling safer and more effective MRI imaging for neuronal diseases by improving the magnetic resonance signal and penetration through biological barriers.
Implementation Method 1
Magnetic resonance imaging (MRI) is an alternative imaging technique, which is widely used in clinical settings. MRI uses magnetic fields and radio waves to generate images of the target tissue or organs in the body.
Implementation Method 2
MRI contrast agents, and in particular iron-based MRI contrast agents, are susceptible agglomeration and exhibit poor in vivo distribution and half-life. MRI contrast agents are typically coated with biocompatible polymers to prevent such agglomeration and to improve their in vivo distribution.
Data Source
AI summary
Provided herein is a nanoparticle comprising a metal core and a polymer shell coating the metal core useful as a magnetic resonance contrast agent.